Journal article
Effectiveness of Adding Everolimus to the First-line Treatment of Advanced Breast Cancer in Premenopausal Women Who Experienced Disease Progression While Receiving Selective Estrogen Receptor Modulators
Abstract
IMPORTANCE: The effectiveness of the mammalian target of rapamycin (mTOR) inhibitor everolimus in premenopausal women with hormone receptor (HR)-positive/ERBB2-negative advanced breast cancer who experienced disease progression while receiving selective estrogen receptor modulators (SERMs) is unknown.
OBJECTIVE: To compare the effectiveness of everolimus plus letrozole vs letrozole alone in premenopausal women with HR-positive/ERBB2-negative …
Authors
Fan Y; Sun T; Shao Z; Zhang Q; Ouyang Q; Tong Z; Wang S; Luo Y; Teng Y; Wang X
Journal
JAMA Oncology, Vol. 7, No. 10,
Publisher
American Medical Association (AMA)
Publication Date
October 1, 2021
DOI
10.1001/jamaoncol.2021.3428
ISSN
2374-2437